• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Screening of and mechanism underlying the action of serum- and glucocorticoid-regulated kinase 3-targeted drugs against estrogen receptor-positive breast cancer
This study provides an experimental and theoretical basis for the research and development of new anti-ER + breast cancer drugs.PMID:35569550 | DOI:10.1016/j.ejphar.2022.174982
Source: European Journal of Pharmacology - May 15, 2022 Category: Drugs & Pharmacology Authors: Duanfang Zhou Xiaoping Yu Yi Song Hongfang Zeng Huan Zhang Bo Chen Yalan Wang Hongyao Li Xu Liu Qichen He Xiaoli Li Weiying Zhou Source Type: research

Ginsenoside Rh1 inhibits tumor growth in MDA-MB-231 breast cancer cells via mitochondrial ROS and ER stress-mediated signaling pathway
Arch Pharm Res. 2022 Mar 24. doi: 10.1007/s12272-022-01377-3. Online ahead of print.ABSTRACTGinsenoside-Rh1 (Rh1) is a ginseng-derived compound that has been reported to exert anticancer effects by regulating cell cycle arrest and apoptosis according to reactive oxygen species (ROS) production. However, the effects of Rh1 on mitochondrial dysfunction are involved in triple negative breast cancer (TNBC) cell apoptosis, and the related molecular mechanisms remain unknown. Rh1 treatment induced cell toxicity less than 50% at 50 μM. In addition, Rh1 induced apoptosis in TNBC cells through cleaved caspase-3 activation and G1/S...
Source: Archives of Pharmacal Research - March 24, 2022 Category: Drugs & Pharmacology Authors: Yujin Jin Diem Thi Ngoc Huynh Kyung-Sun Heo Source Type: research

Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer
CONCLUSION: Our data indicate, for the first time, that CDK7-targeted therapy in ER+ breast cancer ameliorates tamoxifen resistance, at least in part, by inhibiting cancer stemness. Thus, targeting CDK7 might represent a potential approach for relieving tamoxifen resistance in ER+ breast cancer.PMID:35000145 | DOI:10.1007/s43440-021-00346-9
Source: Pharmacological Reports - January 9, 2022 Category: Drugs & Pharmacology Authors: Yasmin M Attia Salama A Salama Samia A Shouman Cristina Ivan Abdelrahman M Elsayed Paola Amero Cristian Rodriguez-Aguayo Gabriel Lopez-Berestein Source Type: research

Lactate Dehydrogenase A or B Knockdown Reduces Lactate Production and Inhibits Breast Cancer Cell Motility in vitro
Conclusion: Enhanced cell motility in endocrine resistant breast cancer cells is at least in part mediated by enhanced extracellular lactate levels, and LDH inhibition might be a promising therapeutic target to inhibit cancer cell motility.
Source: Frontiers in Pharmacology - October 20, 2021 Category: Drugs & Pharmacology Source Type: research

Design and Invitro Characterization of Green Synthesized Magnetic Nanoparticles Conjugated with Multitargeted Poly Lactic Acid Copolymers for Co-delivery of siRNA and Paclitaxel
CONCLUSION: Conjugation of both folic acid and T7-peptide on the surface of micelles compared to separate conjugation of one of these ligands, increased the efficiency of drug and siRNA delivery to breast cancer cells.PMID:34520835 | DOI:10.1016/j.ejps.2021.106007
Source: European Journal of Pharmaceutical Sciences - September 14, 2021 Category: Drugs & Pharmacology Authors: Amin Amani Mohammad Dustparast Mehran Noruzpour Rasool Asghari Zakaria Hossein Ali Ebrahimi Source Type: research

Acyl-CoA synthetase-4 mediates radioresistance of breast cancer cells by regulating FOXM1
Biochem Pharmacol. 2021 Aug 3:114718. doi: 10.1016/j.bcp.2021.114718. Online ahead of print.ABSTRACTThe development of radioresistance during radiotherapy is a major cause of tumor recurrence and metastasis. To provide new insights of the mechanisms underlying radioresistance, we established radioresistant cell lines derived from two different subtypes of breast cancer cells, HER2-positive SK-BR-3 and ER-positive MCF-7 breast cancer cells, by exposing cells to 48∼70 Gy of radiation delivered at 4-5 Gy twice weekly over 9∼10 months. The established radioresistant SK-BR-3 (SR) and MCF-7 (MR) cells were resistant not only...
Source: Biochemical Pharmacology - August 6, 2021 Category: Drugs & Pharmacology Authors: Yun-Suk Kwon Min-Gu Lee Junyoung Baek Nam-Yi Kim Hyunsoo Jang Soyoung Kim Source Type: research

Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer
Publication date: Available online 28 June 2021Source: International Journal of PharmaceuticsAuthor(s): Rahul Chadar, Afsana, Prashant Kesharwani
Source: International Journal of Pharmaceutics - June 29, 2021 Category: Drugs & Pharmacology Source Type: research

Metformin-conjugated micellar system with intratumoral pH responsive de-shielding for co-delivery of doxorubicin and nucleic acid.
Abstract A novel PMet-P(cdmPEG2K) polymeric micellar carrier was developed for tumor-targeted co-delivery of DOX and nucleic acids (NA), based on polymetformin and a structure designed to lose the PEG shell in response to the acidic extracellular tumor environment. NA/DOX co-loaded micelleplexes exhibited enhanced inhibition of cell proliferation compared to DOX-loaded micelles, and displayed a higher level of cytotoxicity at an acidic pH (6.8) which mimicks the tumor microenvironment. The PMet-P(cdmPEG2K) micelles achieved significantly improved transfection with either a reporter plasmid or Cy3-siRNA, and enhanc...
Source: Biochemical Pharmacology - February 2, 2021 Category: Drugs & Pharmacology Authors: Liu Y, Sun J, Huang Y, Chen Y, Li J, Liang L, Xu J, Wan Z, Zhang B, Li Z, Li S Tags: Biochem Pharmacol Source Type: research

Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1
Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, have been widely used to lower cholesterol and prevent cardiovascular diseases. Recent preclinical and clinical studies have shown that statins exert beneficial effects in the management of breast cancer, while the underlying mechanisms remain to be elucidated. Herein, we sought to investigate the effect of statins on the expression of pituitary tumor-transforming gene 1 (PTTG1), a critical gene involved in human breast cancer invasion and metastasis. Our results showed that PTTG1 is highly expressed in malignant Hs578T and MDA-MB-231 breast cancer cel...
Source: Frontiers in Pharmacology - November 4, 2020 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10